# **Neurological Diagnoses in Hospitalized COVID-19 Patients Associated With Adverse Outcomes: A Multinational Cohort Study**

Meghan R Hutch BS**\***, Jiyeon Son MD**\***, Trang T Le PhD**\***, Chuan Hong PhD**\***, Xuan Wang PhD**\***, Zahra Shakeri Hossein Abad PhD**\***, Michele Morris BA, Alba Gutiérrez-Sacristán PhD, Jeffrey G Klann MEng, PhD, Anastasia Spiridou PhD, Ashley Batugo BS, Riccardo Bellazzi MS, PhD, Vincent Benoit PhD, Clara-Lea Bonzel MSc, William A Bryant PhD, Lorenzo Chiudinelli PhD, Kelly Cho, MPH, Priyam Das PhD, Tomás González González MD, David A Hanauer MD, MS, Darren W Henderson BS,Yuk-Lam Ho MPH, Ne Hooi Will Loh MBBS, Adeline Makoudjou MD, Simran Makwana MS, Alberto Malovini PhD, Bertrand Moal MD, PhD, Danielle L Mowery PhD, Antoine Neuraz MD, PhD, Malarkodi Jebathilagam Samayamuthu MD, Fernando J Sanz Vidorreta BS, Emily R Schriver MS, Petra Schubert MPH, Jeffery Talbert PhD, Amelia LM Tan BSc, PhD, Byorn W.L. Tan MBBS, Bryce W.Q. Tan MBBS, Valentina Tibollo MS, Patric Tippman MSc, Guillaume Verdy MSc, William Yuan PhD, Paul Avillach MD, PhD, Nils Gehlenborg PhD, Gilbert S Omenn MD, PhD, The Consortium for Clinical Characterization of COVID-19 by EHR (4CE), Shyam Visweswaran MD, PhD**\*\***, Tianxi Cai ScD**\*\***, Yuan Luo PhD**\*\***, Zongqi Xia MD, PhD**\*\***

[A Consortium for Clinical Characterization of COVID-19 by EHR study (4CE)](https://covidclinical.net/)

------------------------------------------------------------------------

## **Patient Population**

Our study leverages a multinational study of \> 106,000 hospitalized COVID-19 adult and pediatric positive patients from 21 healthcare systems across 6 countries. We examined and report the clinical health outcomes (length of hospital stay and mortality) of COVID-19 patients with concurrent neurological diagnoses.

Specifically, we used ICD codes to stratify patients into three groups of patients with 1) no neurological condition (NNC), 2) a central nervous system condition (CNS), or 3) a peripheral nervous system condition (PNS) in order to evaluate the risk of poor health outcomes by neurologic status.

## **Code and Analysis**

Explore the analysis using our interactive notebooks!

1.  [Patient Characteristics](Patient-Characteristics.html)

2.  [Meta-Analysis Cox-PH: Risk of Poor Health Outcomes](Meta-Analysis-Cox-PH.html)

3.  [Meta-Analysis Kaplan-Meier Survival Curves: Time to Poor Health Outcomes](Meta-Analysis-KM-Survival-Curves.html)

4.  [Meta-Analysis Cox-PH: Sensitivity Analysis: Comorbidity Adjustment and Covariate Evaluation](Meta-Analysis-Cox-PH-Sensitivity-Analysis.html)

To view and run all the code yourself, please navigate to the following repos:

-   [4CE-Phase2.1Neuro R package run locally at each healthcare system](https://github.com/covidclinical/Phase2.1NeuroRPackage)

-   [4CE-Phase2.1Neuro Meta-Analysis](https://github.com/covidclinical/Phase2.1NeuroAnalysis)

*Note: Healthcare system summary and aggregate result files will be made available upon publication of the manuscript*

------------------------------------------------------------------------

[2021 Preprint Available](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4057133)

*Revised Manuscript currently under review*
